SGHT vs. RXST, BBNX, CBLL, DCTH, AVNS, BFLY, BVS, KIDS, NPCE, and AXGN
Should you be buying Sight Sciences stock or one of its competitors? The main competitors of Sight Sciences include RxSight (RXST), Beta Bionics (BBNX), CeriBell (CBLL), Delcath Systems (DCTH), Avanos Medical (AVNS), Butterfly Network (BFLY), Bioventus (BVS), OrthoPediatrics (KIDS), NeuroPace (NPCE), and AxoGen (AXGN). These companies are all part of the "medical equipment" industry.
Sight Sciences vs.
RxSight (NASDAQ:RXST) and Sight Sciences (NASDAQ:SGHT) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, community ranking, institutional ownership, profitability, media sentiment, valuation, risk, dividends and analyst recommendations.
RxSight has a beta of 1.32, suggesting that its share price is 32% more volatile than the S&P 500. Comparatively, Sight Sciences has a beta of 2.41, suggesting that its share price is 141% more volatile than the S&P 500.
78.8% of RxSight shares are held by institutional investors. Comparatively, 55.5% of Sight Sciences shares are held by institutional investors. 9.4% of RxSight shares are held by insiders. Comparatively, 30.9% of Sight Sciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
RxSight has a net margin of -23.92% compared to Sight Sciences' net margin of -63.30%. RxSight's return on equity of -14.00% beat Sight Sciences' return on equity.
RxSight received 32 more outperform votes than Sight Sciences when rated by MarketBeat users. Likewise, 63.41% of users gave RxSight an outperform vote while only 28.99% of users gave Sight Sciences an outperform vote.
RxSight has higher revenue and earnings than Sight Sciences. RxSight is trading at a lower price-to-earnings ratio than Sight Sciences, indicating that it is currently the more affordable of the two stocks.
In the previous week, RxSight had 11 more articles in the media than Sight Sciences. MarketBeat recorded 16 mentions for RxSight and 5 mentions for Sight Sciences. RxSight's average media sentiment score of 1.48 beat Sight Sciences' score of 1.25 indicating that RxSight is being referred to more favorably in the media.
RxSight currently has a consensus target price of $37.90, indicating a potential upside of 139.57%. Sight Sciences has a consensus target price of $3.92, indicating a potential upside of 17.79%. Given RxSight's stronger consensus rating and higher probable upside, equities research analysts clearly believe RxSight is more favorable than Sight Sciences.
Summary
RxSight beats Sight Sciences on 15 of the 18 factors compared between the two stocks.
Get Sight Sciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for SGHT and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Sight Sciences Competitors List
Related Companies and Tools
This page (NASDAQ:SGHT) was last updated on 5/22/2025 by MarketBeat.com Staff
Buy SGHT Stock Free SGHT Stock Alerts